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Background: In normal conditions FSHR are expressed in granulosa cells of the ovary and Sertoli cells of the testis.
They can be expressed also in gonadal tumours. However, recently the expression of FSHR was found in tumoral
cells and intra-tumoral blood vessels of many other tumours, including thyroid tumours. Aim of this study was to
see whether the expression of FSHR can be useful in the differentiation of benign and malignant thyroid lesions.
Methods: 44 samples of surgically excised thyroids were immunostained with anti- FSHR antibody raised against
1–190 amino acid sequence from the human FSHR.
Results: Non-neoplastic thyroid follicles (i.e. the follicles situated outside the tumour) do not show the
immunostaining for FSHR. The same concerns the majority of follicular adenomas. In contrast, 87.5% of follicular
cancers, the same percentage of papillary cancers and all the examined undifferentiated cancers showed the FSHR
immunopositivity of tumoral cells. A tendency towards the higher frequency of FSHR – positive blood vessels also
concerns malignant thyroid tumours.
Conclusions: The ectopic FSHR immunostaining seems to be useful to differentiate malignant from benign lesions,
especially follicular cancers from follicular adenomas. However, the further studies on larger material are needed.Background
The follitropin receptors (FSHR) are normally expressed
in granulosa cells of the ovary and in Sertoli cells of the
testis. It is well known that FSHR can be also expressed in
gonadal tumours [1]. Some years ago Radu et al. [2]
reported on the ectopic expression of FSHR in the endo-
thelium of intratumoral and peritumoral blood vessels
in several malignant extra-gonadal tumours [2]. We con-
firmed this finding in endocrine tumours, including pituit-
ary adenomas, adrenal benign and malignant tumours and
neuroendocrine tumours of lungs and of the alimentary
tract (carcinoids). Moreover, we also observed the positive
immunostaining with anti-FSHR antibody in tumoral cells
of the investigated tumours [3,4]. The latter observations
corroborate with the earlier findings of Ben-Josef et al. [5]* Correspondence: marek.pawlikowski@umed.lodz.pl
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unless otherwise stated.who reported on the FSHR expression in androgen-
independent prostate cancer cells PC3 and DU145 and
that of Sardella et al. [6] who found the expression of
FSHR in the tumoral cells of neuroendocrine pancreatic
tumours. The recent studies from our [7,8] and other [9]
laboratory showed that the ectopic FSHR immunostaining
is also present in thyroid neoplasms.
The aim of the study was to re-evaluate the possible
usefulness of FSHR immunostaining to differentiate be-
tween benign and malignant thyroid lesions, especially
between the follicular adenomas and follicular cancers.
Methods
Forty four thyroid samples, obtained during surgery, were
examined. The samples included 4 undifferentiated can-
cers, 16 papillary cancers, 16 follicular cancers and 8 fol-
licular adenomas. FSHR immunostaining was performed
on paraffin sections using the rabbit anti-human FSHR
polyclonal antibody raised against 1–190 amino acid se-
quence from the human FSH-R (sc-13935, Santa Cruzentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 2 Follicular adenoma. Immunostaining with FSHR antibody
negative in majority of cells, positive only in few cells. Final
magnification 200×.
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dilution of 1:100. The visualization of immunostaining
was done using the Dako REAL EnVision Detection Sys-
tem (Dako-Cytomation, Denmark). The immunostaining
intensity for FSHR in the tumoral cells was scored using a
semiquantitative scale: negative staining (score 0), weak
staining (score: 1), moderate staining (score: 2) and strong
staining (score: 3). Only strong (score 3) or moderate
(score 2) immunostaining was considered as meaningful.
The slides stained with the omission of the primary anti-
body served as negative controls. The study was approved
by the local ethical committee of the Medical University of
Lodz, decision No RRN/151//14/KE.
Results
The ectopic FSHR immunostaining was absent in non-
neoplastic thyroid follicles (Figure 1) (i.e. the follicles sit-
uated outside the tumour) and in the majority (all but
two, Figure 2) of follicular adenomas. In contrast, the
FSHR expression can be detected in tumoral cells of
majority (88.8%, 32/36) of thyroid cancers. The positive
FSHR immunostaining of tumoral cells was shown in 14
from 16 examined follicular cancers (87.5%, Figure 3).
The same could be observed in 14 from 16 examined
papillary cancers (87.5%, Figure 4) and in the all (4/4)
undifferentiated cancers (Figure 5). The positive FSHR
immunostaining is also present in the walls (mainly in
endothelium) of some intra- or peri-tumoral blood ves-
sels (Figure 6). The immunopositive blood vessels were
detected in 3/8 (37.5%) follicular adenomas, 5/16 (31%)
follicular cancers, 9/16 (56%) papillary cancers and in
3/4 (75%) undifferentiated cancers.
Discussion
The observations presented above confirm that, like in
the other human neoplasms, thyroid cancers in the greatFigure 1 Non-neoplastic thyroid epithelium. Negative staining
for FSHR. Final magnification 200×.majority express FSHR in contrast to the non-neoplastic
thyroid epithelium. The expression of FSHR may some-
times occur also in the benign thyroid lesions, like thyroid
follicular adenomas but that is scarce. In contrast, Liu et al.
[9] reported that FSHR expression is greater in thyroid ad-
enomas than in papillary and poorly differentiated cancers.
However, their material did not include the follicular can-
cers. The difference in FSHR expression between follicular
cancers and follicular adenomas, as it was shown in the
present study, seems to be of importance for a diagnosis.
The differentiation among them by a pathologist on the
basis of the morphological features is sometimes very diffi-
cult. Thus, the immunopositivity of FSHR could serve as an
additional marker of malignancy. However, the further
studies on larger material are needed in this respect.
There are many data concerning other tumours indi-
cating the relationship of ectopic FSHR expression andFigure 3 Follicular cancer. Immunostaining with FSHR antibody.
Final magnification 400×.
Figure 4 Papillary cancer. Immunostaining with FSHR antibody.
Final magnification 200×.
Figure 6 Blood vessels immunopositive FSHR. Follicular cancer.
Final magnification 400×.
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androgen-independent prostate cancer cells which are
considered as less differentiated than androgen –
dependent ones [5]. In liposarcomas, FSHR expression
was observed in more cases of poorly differentiated than
in well differentiated tumours. In contrast, benign lipomas
and the normal fat is FSHR-negative [10]. In neuroendo-
crine tumours, the FSHR-positive blood vessels are more
often present in the samples with higher proliferation
index [4]. In pituitary adenomas, the expression of FSHR
in tumoral cells is prevalent in invasive and proliferating,
it means more aggressive tumours [11]. It remains un-
known, whether the FSHR protein detectable in thyroid
tumours is biologically active. If so, it may be also relevant
for the outcome of tumours because, like in the ovary and
ovarian cancers, FSHR may mediate the stimulatory effect
of FSH on cell proliferation and angiogenesis [12,13] and
the inhibitory effect on apoptosis [14].Figure 5 Undifferentiated cancer. Immunostaining with FSHR
antibody. Final magnification 400×.Conclusions
The ectopic FSHR immunostaining seems to be useful to
differentiate malignant from benign thyroid lesions, espe-
cially follicular cancers from follicular adenomas. How-
ever, the further studies on larger material are needed.
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